Respiratory Syncytial Virus (RSV) is a common and highly contagious virus that infects the respiratory tract, primarily affecting the lungs and airways.
Introduction Paxlovid, the pill that has become the go-to treatment for COVID-19 treatment, was granted full approval in May by the Food And Drug Administration (FDA) for the treatment of mild-to-moderate…
Before we get into understanding the possible links between autoimmunity and COVID-19, it is imperative that we understand what autoantibodies are and how they affect our body. These self-attacking antibodies…
History of the Nipah virus in India In 2001, the first outbreak of Nipah virus was occurred in West Bengal that caused as many as 45 deaths. Again, it happened…
A 12 year old boy, Muhammad Hashim dies of Nipah virus in Kozhikode on Sunday morning. The Central Government has confirmed the case and a team of National Centre for…
With a daily count of over 30,000 cases for the fourth consecutive day, Kerala accounts for around 70% of he total COVID-19 cases in the country. Active cases are over 2 lakhs and…
The vaccine by Pfizer-BioNTech is the first vaccine that has been lincensed for COVID-19. The mRNA vaccine has shown to prevent 95 percent of COVID-19 during the clinical trials and can…
Zydus Cadila’s DNA based vaccine ZyCoV-D becomes the first vaccine to receive emergency use authorization for children above 12 years of age. The three-dose vaccine has an efficacy rate of…
Lambda, a new coronavirus variant has been declared as a “variant of interest” by the World Health Organization (WHO). 31 countries including United States, United Kingdom, France, Italy, Germany and…
Health ministry on Monday informed that as many as 32.8 crore doses of Covid-19 vaccines have been administered since the start of the vaccination drive that began from January 16….
Autoimmunity cancer cancer research cancer therapy CDSCO covid-19 covid in children Diabetes drug Elderly Health FDA healthcare immune response Kerala mutations Nipah virus pandemic PCOS pharma Pharmaceutical market pharma sector protein-based vaccines sars-cov-2 therapy third wave Treatment vaccine variants WHO zydus cadila